# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Luca Issi reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and maintains $40 price t...
4D-175 comprises the proprietary low-dose intravitreal R100 AAV vector and a codon-optimized transgene encoding a highly functi...
24-week landmark safety and clinical activity data for 45 patients enrolled in the Population Extension cohort expected to be p...
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF inj...
- SEC Filing
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.
HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains...